Crystal Rock Capital Management Decreased By $1.31 Million Its Cheesecake Factory (CAKE) Holding, 3 Analysts Bullish Seattle Genetics, Inc. (SGEN)

June 1, 2017 - By Henry Gaston

Among 10 analysts covering Seattle Genetics (NASDAQ:SGEN), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Seattle Genetics had 19 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Outperform” rating given on Monday, October 10 by RBC Capital Markets. Leerink Swann maintained the shares of SGEN in report on Friday, August 14 with “Outperform” rating. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Outperform” rating by RBC Capital Markets on Tuesday, December 6. The firm has “Neutral” rating by Piper Jaffray given on Friday, October 30. As per Wednesday, July 27, the company rating was downgraded by Cantor Fitzgerald. Goldman Sachs initiated the shares of SGEN in report on Wednesday, November 18 with “Sell” rating. The rating was downgraded by Barclays Capital to “Equal-Weight” on Tuesday, November 29. The firm has “Outperform” rating given on Thursday, January 21 by Credit Suisse. On Tuesday, August 25 the stock rating was maintained by William Blair with “Buy”. The stock has “Underperform” rating by Bank of America on Friday, February 10. See Seattle Genetics, Inc. (NASDAQ:SGEN) latest ratings:

16/03/2017 Broker: Oppenheimer Rating: Perform Initiates Coverage On
10/02/2017 Broker: Bank of America Old Rating: Neutral New Rating: Underperform Downgrade
12/12/2016 Broker: Credit Suisse Old Rating: Outperform New Rating: Neutral Downgrade
06/12/2016 Broker: RBC Capital Markets Rating: Outperform Old Target: $62 New Target: $72 Maintain

Crystal Rock Capital Management decreased Cheesecake Factory Inc (CAKE) stake by 22.61% reported in 2016Q4 SEC filing. Crystal Rock Capital Management sold 22,138 shares as Cheesecake Factory Inc (CAKE)’s stock declined 4.69%. The Crystal Rock Capital Management holds 75,782 shares with $4.54M value, down from 97,920 last quarter. Cheesecake Factory Inc now has $2.83B valuation. The stock rose 0.14% or $0.08 reaching $59.06. About 156,833 shares traded. Cheesecake Factory Inc (NASDAQ:CAKE) has risen 21.63% since June 1, 2016 and is uptrending. It has outperformed by 4.93% the S&P500.

Among 10 analysts covering The Cheesecake Factory Incorporated (NASDAQ:CAKE), 3 have Buy rating, 2 Sell and 5 Hold. Therefore 30% are positive. The Cheesecake Factory Incorporated had 20 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Buy” on Thursday, October 27. Telsey Advisory Group maintained it with “Market Perform” rating and $55 target in Tuesday, October 27 report. The firm has “Market Perform” rating by Telsey Advisory Group given on Tuesday, September 29. The stock of Cheesecake Factory Inc (NASDAQ:CAKE) earned “Buy” rating by Argus Research on Tuesday, November 15. The company was maintained on Thursday, July 23 by Wunderlich. The stock of Cheesecake Factory Inc (NASDAQ:CAKE) earned “Buy” rating by Stifel Nicolaus on Thursday, July 23. Maxim Group initiated the shares of CAKE in report on Tuesday, February 9 with “Buy” rating. The stock has “Outperform” rating by Telsey Advisory Group on Wednesday, November 9. The rating was downgraded by Stephens to “Equal-Weight” on Wednesday, November 16. The company was upgraded on Tuesday, October 27 by BTIG Research.

Analysts await Cheesecake Factory Inc (NASDAQ:CAKE) to report earnings on July, 26. They expect $0.86 EPS, up 10.26% or $0.08 from last year’s $0.78 per share. CAKE’s profit will be $41.21 million for 17.17 P/E if the $0.86 EPS becomes a reality. After $0.72 actual EPS reported by Cheesecake Factory Inc for the previous quarter, Wall Street now forecasts 19.44% EPS growth.

Investors sentiment increased to 1.09 in 2016 Q4. Its up 0.08, from 1.01 in 2016Q3. It is positive, as 24 investors sold CAKE shares while 99 reduced holdings. 51 funds opened positions while 83 raised stakes. 44.02 million shares or 4.42% more from 42.16 million shares in 2016Q3 were reported. Bamco invested 0.19% in Cheesecake Factory Inc (NASDAQ:CAKE). Td Asset Management invested in 124,230 shares. First Citizens Bancorp And Trust Communications has invested 0.04% in Cheesecake Factory Inc (NASDAQ:CAKE). Prudential Financial owns 27,929 shares. Bessemer Inc holds 441,927 shares or 0.12% of its portfolio. Jacobs Levy Equity Mngmt, New Jersey-based fund reported 72,623 shares. Commonwealth Equity Svcs Inc holds 6,091 shares. Ameritas Investment Prtnrs Inc reported 34,120 shares. Rothschild Asset Incorporated has invested 0.25% of its portfolio in Cheesecake Factory Inc (NASDAQ:CAKE). Disciplined Growth Inc Mn holds 1.4% of its portfolio in Cheesecake Factory Inc (NASDAQ:CAKE) for 1.03 million shares. Long Road Invest Counsel Ltd Llc invested in 1.6% or 34,819 shares. Reilly Financial Advsr reported 0% stake. Lazard Asset Mgmt invested in 0% or 100 shares. 205,772 are held by Principal Gru. Amer Century reported 0.02% in Cheesecake Factory Inc (NASDAQ:CAKE).

Since January 12, 2017, it had 1 buying transaction, and 11 sales for $2.63 million activity. ZURZOLO DEBBY R sold $91,721 worth of Cheesecake Factory Inc (NASDAQ:CAKE) on Thursday, January 12. $832,164 worth of stock was sold by BENN DOUG on Wednesday, March 8. Another trade for 400 shares valued at $23,288 was made by PITTAWAY DAVID BRUCE on Tuesday, May 23. $212,288 worth of Cheesecake Factory Inc (NASDAQ:CAKE) was sold by SLOMANN CHERYL. $773,653 worth of Cheesecake Factory Inc (NASDAQ:CAKE) shares were sold by KRANSDORF JEROME I.

Crystal Rock Capital Management increased Newell Brands Inc (NYSE:NWL) stake by 90,700 shares to 174,150 valued at $7.78 million in 2016Q4. It also upped Walgreens Boots Alliance Inc stake by 8,700 shares and now owns 55,010 shares. Red Rock Resorts Inc was raised too.

Investors sentiment increased to 1.2 in 2016 Q4. Its up 0.20, from 1 in 2016Q3. It increased, as 30 investors sold Seattle Genetics, Inc. shares while 73 reduced holdings. 60 funds opened positions while 64 raised stakes. 135.77 million shares or 1.02% less from 137.16 million shares in 2016Q3 were reported. Architects invested in 0.02% or 1,421 shares. Tocqueville Asset Mgmt Lp holds 0.02% or 36,190 shares in its portfolio. Sterling Mgmt Limited, a North Carolina-based fund reported 29,469 shares. State Street holds 0.01% or 2.57M shares in its portfolio. Oregon Public Employees Retirement Fund reported 0.02% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). 58,292 were reported by Ironbridge Cap Lp. Pnc Fincl Group owns 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 3,265 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 21,705 shares. Carl Domino Inc owns 5,400 shares. Metropolitan Life Insur New York invested in 6,607 shares or 0% of the stock. Vantage Invest Advsr Ltd Liability Company has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 600 shares. Nordea Investment Management Ab reported 2,762 shares. California State Teachers Retirement Sys reported 199,807 shares. Envestnet Asset Mgmt Inc, a Illinois-based fund reported 3,636 shares. First Quadrant L P Ca accumulated 1,000 shares or 0% of the stock.

About 132,679 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since June 1, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has market cap of $9.22 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It currently has negative earnings. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate .

Since December 6, 2016, it had 0 insider buys, and 10 insider sales for $9.52 million activity. 14,465 shares were sold by SIEGALL CLAY B, worth $957,145 on Tuesday, December 6. 10,000 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $633,834 were sold by Cline Darren S. Shares for $627,527 were sold by HIMES VAUGHN B. $824,042 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) was sold by DOBMEIER ERIC.